Generated: April 23, 2017
|Title:||Hyperlipemia therapeutic agent|
|Abstract:||The present invention relates to a hyperlipemia therapeutic agent comprising pitavastatins and eicosapentaenoic acid or an ester derivative thereof as effective ingredients.According to the present invention, a type IIb and type IV hyperlipemia therapeutic agent having an excellent effect of lowering the cholesterol and triglyceride in blood is provided.|
|Inventor(s):||Aoki; Taro (Tokorozawa, JP), Yamaguchi; Junji (Higashimurayama, JP), Sasaki; Yusuke (Higashimurayama, JP)|
|Assignee:||KOWA Co., Ltd. (Nagoya, JP) Nissan Chemical Industries, Ltd. (Tokyo, JP)|
1. A method for treating hypertriglyceridemia in a patient in need of such treatment comprising administering a synergistically effective blood-triglyceride decreasing amount
of a combination of a pitavastatin and eicosapentaenoic acid or an ester thereof.
2. A method according to claim 1, wherein the pitavasitin is pitavastin calcium and the eicosapentaenoic acid or ester thereof is ethyl eicosapentaenoate.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.